Want to see AU:AYA full AI Analyst Report?
Top Page
Artrya Limited
(Sydney:AYA)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$4.00
â–Ľ(-19.84% Downside)
Action:Reiterated
Date:08/20/26
The score is held down primarily by very weak financial performance—minimal revenue, large and worsening losses, and heavy ongoing cash burn—despite the benefit of low debt. Technicals add a modest offset with long-term price support above the 200-day average, but near-to-medium term momentum remains weak (negative MACD and price below key moving averages). Valuation is also pressured because earnings are negative and there is no dividend yield data.
Positive Factors
Specialized cardiovascular AI focus
A focused cardiovascular application gives Artrya a clearly defined product purpose within digital health. Its software targets disease detection and clinical risk assessment, creating a specialized platform that can be developed around established imaging and cardiology workflows over time.
Negative Factors
Minimal commercial revenue
The very small revenue base shows that commercial monetization has not yet become meaningful relative to the company’s operating needs. This limits internal funding capacity and indicates that future business progress remains dependent on converting the product into material provider revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized cardiovascular AI focus
A focused cardiovascular application gives Artrya a clearly defined product purpose within digital health. Its software targets disease detection and clinical risk assessment, creating a specialized platform that can be developed around established imaging and cardiology workflows over time.
Read all positive factors
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$682.85M
Dividend YieldN/A
Average Volume (3M)772.08K
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue Growth<0.01%
EPS Growth2.08%
CountryAU
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.17
Shares Outstanding163,360,290
10 Day Avg. Volume630,095
30 Day Avg. Volume772,078
Financial Highlights & Ratios
PEG Ratio6.46
Price to Book (P/B)11.56
Price to Sales (P/S)32321.70
P/FCF Ratio-56.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.75Price Target Upside35.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$9.23M
Artrya Limited Business Overview & Revenue Model
Company Description
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages...
How the Company Makes Money
Artrya’s primary revenue model is expected to come from commercializing its AI-powered cardiovascular analysis software to healthcare providers, typically through software licensing and/or subscription (software-as-a-service) arrangements. Under t...
Artrya Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
64
Positive
Cash Flow
14
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.00K | 28.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.23M | -15.99M | -13.25M | -552.00K | -202.00K |
| EBITDA | -26.04M | -16.21M | -13.96M | -10.51M | -16.40M |
| Net Income | -25.18M | -16.41M | -14.00M | -11.14M | -17.16M |
Balance Sheet | |||||
| Total Assets | 85.35M | 23.68M | 19.01M | 33.09M | 43.87M |
| Cash, Cash Equivalents and Short-Term Investments | 74.17M | 11.33M | 7.28M | 20.41M | 35.56M |
| Total Debt | 247.00K | 624.00K | 949.00K | 1.21M | 1.37M |
| Total Liabilities | 7.06M | 2.39M | 2.21M | 2.53M | 3.23M |
| Stockholders Equity | 78.29M | 21.29M | 16.80M | 30.56M | 40.64M |
Cash Flow | |||||
| Free Cash Flow | -15.91M | -14.53M | -15.41M | -16.69M | -15.99M |
| Operating Cash Flow | -15.77M | -14.27M | -15.41M | -10.74M | -9.61M |
| Investing Cash Flow | -30.50M | 7.00K | 2.71M | 16.27M | -26.59M |
| Financing Cash Flow | 79.00M | 18.46M | -299.00K | -245.00K | 38.53M |
Artrya Limited Technical Analysis
Negative
4.99
Price Trends
5.02
Negative
4.83
Negative
4.22
Negative
Market Momentum
-0.19
Positive
36.92
Neutral
5.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AYA, the sentiment is Negative. The current price of 4.99 is above the 20-day moving average (MA) of 4.62, below the 50-day MA of 5.02, and above the 200-day MA of 4.22, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 36.92 is Neutral, neither overbought nor oversold. The STOCH value of 5.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AYA.
Artrya Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$27.67M | 18.13 | 13.72% | ― | 42.25% | ― | |
61 Neutral | AU$141.73M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$35.44M | -1.91 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$682.85M | -24.02 | -30.04% | ― | <0.01% | 2.08% | |
47 Neutral | AU$65.80M | -7.37 | -24.29% | ― | -17.35% | -47.29% | |
44 Neutral | AU$58.70M | -8.87 | -57.06% | ― | 603.32% | 10.57% |
* Healthcare Sector Average
AU:AYA
Artrya Limited
4.00
1.82
83.49%
AU:M7T
Mach7 Technologies
0.28
-0.04
-12.70%
AU:RHT
Resonance Health Ltd
0.06
0.02
62.86%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.12
-50.00%
AU:SHG
Singular Health Group Ltd
0.19
-0.11
-36.67%
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
Artrya Limited Corporate Events
Artrya Added to S&P/ASX 300 in September Index Rebalance
Sep 4, 2026
SP Dow Jones Indices has announced its September 2026 quarterly rebalance of the SP/ASX indices, implementing a series of additions and removals across the SP/ASX 50, 100, 200, and 300. Among these changes, Artrya Limited is set to join the SP/ASX...
Artrya Seeks ASX Quotation for Additional Ordinary Shares
Sep 1, 2026
Artrya Limited has applied to the ASX for quotation of 10,000 ordinary fully paid shares, with the new securities to be issued on 1 September 2026. The modest share issuance reflects routine capital management activity and slightly expands the com...
Artrya issues new shares under employee incentive plan and confirms regulatory compliance
Sep 1, 2026
Artrya Limited has issued 10,000 ordinary shares following the exercise of vested employee incentive performance rights, reflecting the company’s ongoing use of equity-based remuneration to retain and motivate staff. The company has lodged a...
Artrya Issues New Shares on Employee Incentive Conversion
Aug 27, 2026
Artrya Limited has issued 130,002 ordinary shares following the exercise of vested employee incentive performance rights, expanding its share capital as part of its remuneration and incentive framework. The company also confirmed that the new shar...
Artrya Seeks ASX Quotation for Additional Ordinary Shares
Aug 25, 2026
Artrya Limited, listed on the ASX under the code AYA, has lodged an application for quotation of additional ordinary fully paid shares. The filing confirms the company’s identity and registration details but does not disclose specific inform...
Artrya issues new shares on employee incentives and lodges cleansing notice
Aug 25, 2026
Artrya Limited has issued 256,666 fully paid ordinary shares following the exercise of vested employee incentive performance rights and restricted stock units, and has applied for their quotation on the ASX. The move modestly increases the company...
Artrya strengthens board with appointment of healthcare veteran Helen Kurincic
Aug 19, 2026
Artrya Limited has appointed experienced healthcare and imaging executive Helen Kurincic as a Non-Executive Director, effective 20 August 2026, to strengthen its board as the company scales commercial operations. Kurincic brings more than three de...
Artrya lodges ASX corporate governance statement for FY 2026
Aug 19, 2026
Artrya Limited has lodged its annual corporate governance statement for the year ended 30 June 2026, confirming compliance with ASX Corporate Governance Council principles. The statement, approved by the board, is hosted on the company’s web...
Artrya Details 2026 Governance Framework and Committee Approach
Aug 19, 2026
Artrya Limited has released its 2026 Corporate Governance Statement, confirming broad adherence to the ASX Corporate Governance Council’s fourth edition principles. The board has adopted a formal charter defining roles for directors, the cha...
Artrya Widens Annual Loss but Boosts Net Tangible Assets
Aug 19, 2026
Artrya Limited reported revenue from ordinary activities of just $28,000 for the year ended 30 June 2026 and a significantly wider net loss after tax of $25.2 million, up 53.5% on the prior year. No dividends were paid or declared, and basic and d...
UBS Group AG Exits Substantial Shareholding in Artrya Limited
Aug 3, 2026
UBS Group AG and its related bodies corporate have notified Artrya Limited that they ceased to be a substantial shareholder in the company as of 30 July 2026. The change in UBS’s relevant interest in Artrya’s voting securities reflects...
Artrya accelerates U.S. rollout of AI cardiac platform as FDA-ready flow module nears launch
Jul 28, 2026
Artrya reported accelerating U.S. adoption of its Salix platform, with Tanner Health now using Salix Coronary Anatomy and Plaque routinely across five hospitals and Northeast Georgia Health System going live as a second revenue-generating customer...
Artrya’s Salix Platform Goes Live at Northeast Georgia Health System
Jul 22, 2026
Artrya Limited has commenced clinical use of its Salix AI-powered cloud platform at Northeast Georgia Health System, with the first patient scans processed and revenue now being generated. The deployment marks the company’s second U.S. custo...
Artrya Updates Capital Structure as 975,000 Options Cease
Jul 15, 2026
Artrya Limited has notified the market of the cessation of several tranches of options previously on issue, as part of an update to its capital structure. The options, each with different exercise prices and expiring in June 2027, have been remove...
Artrya Director Ridgeway Lets 750,000 Options Expire Unexercised
Jul 10, 2026
Artrya Limited has reported a change in director Bernie Ridgeway’s relevant interests, specifically relating to options previously held through Wear Services Pty Ltd as part of his indirect shareholding arrangements. The notice details exist...
Artrya Issues New Unquoted Equity Under Employee Incentive Schemes
Jul 7, 2026
Artrya Limited has issued new unquoted equity securities under its employee incentive schemes, comprising 675,000 performance rights and 207,500 restricted stock units dated 6 July 2026. The move expands the company’s pool of incentive-based...
Artrya Seeks ASX Quotation for Additional 57,000 Shares
Jun 25, 2026
Artrya Limited has applied for quotation on the ASX of 57,000 ordinary fully paid shares under its existing ticker AYA, with an issue date of June 25, 2026. The additional securities, arising from the exercise or conversion of existing options or ...
Artrya issues new shares on option exercise and lodges cleansing notice
Jun 25, 2026
Artrya Limited has issued 57,000 fully paid ordinary shares following the exercise of vested unlisted options, adding a small tranche of equity to its capital base. The company has lodged an application for quotation of the new shares and released...
Artrya Director Increases Indirect Shareholding Through Option Exercise
Jun 18, 2026
Artrya Limited has disclosed a change in the indirect shareholding of director Bernie Ridgeway, following the exercise of stock options held through Wear Services Pty Ltd , an entity where he serves as director and beneficiary. The transaction, da...
Artrya Seeks ASX Quotation for 1.75 Million New Shares
Jun 18, 2026
Artrya Limited has applied for quotation of 1,750,000 new ordinary fully paid shares on the Australian Securities Exchange. The securities, issued on June 18, 2026, arise from the exercise of options or conversion of other convertible instruments ...
Artrya issues 1.75m shares on option exercise and confirms regulatory compliance
Jun 18, 2026
Artrya Limited has issued 1,750,000 fully paid ordinary shares following the exercise of vested unlisted options linked to senior leadership, including an associate of co-founder and CEO John Konstantopoulos and an entity associated with director ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.